
Sign up to save your podcasts
Or


In this interview, Spencer King and David Fitchett discuss the relationship between hypoglycemia outcomes and empagliflozin treatment in the EMPA-REG OUTOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).
By American College of Cardiology3.8
5454 ratings
In this interview, Spencer King and David Fitchett discuss the relationship between hypoglycemia outcomes and empagliflozin treatment in the EMPA-REG OUTOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

139 Listeners

319 Listeners

498 Listeners

169 Listeners

884 Listeners

291 Listeners

140 Listeners

1,154 Listeners

40 Listeners

195 Listeners

91 Listeners

363 Listeners

429 Listeners

371 Listeners

32 Listeners